<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03587493</url>
  </required_header>
  <id_info>
    <org_study_id>2018-09</org_study_id>
    <nct_id>NCT03587493</nct_id>
  </id_info>
  <brief_title>T-lymphocytes CD8+/HLA-DR+ and Acute Rejection After Lung Transplantation</brief_title>
  <official_title>Activated Cytotoxic T-lymphocytes CD8+/HLA-DR+ and Acute Cellular Rejection After Lung Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vaincre la Mucoviscidose</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of the study is to identify associations between acute rejection and the&#xD;
      increase of T (CD4/CD8) and B circulating lymphocytes expressing specific markers of&#xD;
      activation and differentiation (HLA-DR, CD25, CD38, CD45RO, CCR7).&#xD;
&#xD;
      110 adults over 18 years, on national waiting list for a first lung transplantation in the&#xD;
      centers of Marseille and Strasbourg, whatever the lung disease, and who will be transplanted&#xD;
      and benefit immunosuppressive induction therapy that specifically targets T lymphocytes will&#xD;
      be included. Peripheral venous blood sampling just prior to pulmonary transplantation, at day&#xD;
      15 and one month post-transplant will be realized for lymphocyte phenotyping by flow&#xD;
      cytometry (CD45, CD3, CD4, CD8, CD19, HLA-DR, CD25, CD38, CD45RO, CCR7). Acute rejection will&#xD;
      be evaluated at 1 month and 1 year post-transplant by trans-bronchial biopsies.&#xD;
&#xD;
      The two main perspectives are to 1) find a specific, non-invasive, blood-based diagnostic&#xD;
      marker of acute post-lung transplant rejection with diagnostic performance equivalent to&#xD;
      trans-bronchial biopsy 2) demonstrate a specific blood marker, non-invasive, predictive of&#xD;
      acute rejection in order to adapt immunosuppressive therapy early and reduce the occurrence&#xD;
      of this risk.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of the study is to identify associations between acute rejection and the&#xD;
      increase of T (CD4/CD8) and B circulating lymphocytes expressing specific markers of&#xD;
      activation and differentiation (HLA-DR, CD25, CD38, CD45RO, CCR7).&#xD;
&#xD;
      110 adults over 18 years, on national waiting list for a first lung transplantation in the&#xD;
      centers of Marseille and Strasbourg (France), whatever the lung disease, and who will be&#xD;
      transplanted and benefit immunosuppressive induction therapy that specifically targets T&#xD;
      lymphocytes will be included. Peripheral venous blood sampling just prior to pulmonary&#xD;
      transplantation, at day 15 and one month post-transplant will be realized for lymphocyte&#xD;
      phenotyping by flow cytometry (CD45, CD3, CD4, CD8, CD19, HLA-DR, CD25, CD38, CD45RO, CCR7).&#xD;
      Acute rejection will be evaluated at 1 month and 1 year post-transplant by trans-bronchial&#xD;
      biopsies.&#xD;
&#xD;
      The two main perspectives are to 1) find a specific, non-invasive, blood-based diagnostic&#xD;
      marker of acute post-lung transplant rejection with diagnostic performance equivalent to&#xD;
      trans-bronchial biopsy 2) demonstrate a specific blood marker, non-invasive, predictive of&#xD;
      acute rejection in order to adapt immunosuppressive therapy early and reduce the occurrence&#xD;
      of this risk.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 13, 2018</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>T-lymphocytes CD8/HLA-DR+</measure>
    <time_frame>at day 15 post lung transplantation</time_frame>
    <description>comparison of the level of T-lymphocytes CD8/HLA-DR+ at day 15 post lung transplantation between recipients who developed acute cellular rejection at 1 month post-transplant and those who not.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Transplant Failure</condition>
  <arm_group>
    <arm_group_label>EXPERIMENTAL GROUP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>110 adults, on national waiting list for a first lung transplantation in the centers of Marseille and Strasbourg, whatever the lung disease, and who will be transplanted and benefit immunosuppressive induction therapy that specifically targets T lymphocytes will be included.&#xD;
Blood sample analysis will be performed</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>BLOOD SAMPLE ANALYSIS</intervention_name>
    <description>Peripheral venous blood sampling just before lung transplantation, at day 15 and at post-transplantation M1 for lymphocyte phenotyping by cytometry</description>
    <arm_group_label>EXPERIMENTAL GROUP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt;18 years old&#xD;
&#xD;
          -  French national waiting list of lung transplantation&#xD;
&#xD;
          -  Transplanted in Marseille or Strasbourg (France)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt;18 years old&#xD;
&#xD;
          -  Refused to participate&#xD;
&#xD;
          -  Redo lung transplantation&#xD;
&#xD;
          -  Other organ transplanted&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>EMILIE GARRIDO PRADALIE</last_name>
    <role>Study Director</role>
    <affiliation>APHM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BENJAMIN COIFFARD, MD</last_name>
    <phone>+33 491964355</phone>
    <email>Benjamin.COIFFARD@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assistance Publique Des Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <state>Paca</state>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BENJAMIN COIFFARD, MD</last_name>
      <phone>+33 491964355</phone>
      <email>Benjamin.COIFFARD@ap-hm.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 3, 2018</study_first_submitted>
  <study_first_submitted_qc>July 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2018</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

